- PR Newswire•9 days ago
SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical stage immuno-oncology drug development company, today announced results from a pre-clinical study evaluating the potential benefits of using MabVax's HuMab-5B1antibody, MVT-5873, currently in Phase I clinical trials for the treatment of metastatic pancreatic cancer with Halozyme Therapeutic's (HALO) investigational drug PEGPH20, which targets the tumor microenvironment potentially allowing increased access of co-administered cancer drug therapies to solid tumors. PEGPH20 is currently in phase III clinical development for metastatic pancreatic cancer and in phase I clinical trials for non-small cell lung cancer, gastric cancer, and metastatic breast cancer. Results from the preclinical study were positive demonstrating improvement in accumulation of MVT-5873 on tumors in an animal model of pancreatic cancer when administered in sequence with PEGPH20.
- Motley Fool•19 days ago
Shares rose in response to the release of upbeat clinical data from an important phase 2 study.
- PR Newswire•20 days ago
SAN DIEGO, Feb. 1, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
HALO : Summary for Halozyme Therapeutics, Inc. - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||12.10 x 400|
|Ask||14.22 x 200|
|Day's Range||12.44 - 12.79|
|52 Week Range||7.18 - 14.38|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-22.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|